Calidi Biotherapeutics director Allan Camaisa to step down at 2026 annual meeting; Board reduced to 5

Calidi Biotherapeutics, Inc.

Director Allan J. Camaisa will not stand for re-election; term expires at 2026 annual meeting; no disagreement with company.
Board reduced from six to five directors effective at the 2026 annual meeting.
Scott Leftwich appointed to Audit Committee effective April 1, 2026.
Camaisa's departure is not due to any disagreement with company operations or policies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.